Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05383677
Other study ID # ESR-21-21284
Secondary ID 2022-000609-28
Status Recruiting
Phase Phase 2
First received
Last updated
Start date October 1, 2022
Est. completion date August 1, 2024

Study information

Verified date December 2022
Source University Medical Center Groningen
Contact Hendrika Bootsma
Phone +315036129456
Email h.bootsma@umcg.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The ANISE-II study is a randomized, double-blind, placebo-controlled phase IIa proof-of-concept trial. Thirty patients with primary Sjögren's syndrome (pSS) are randomized in a 2:1 ratio to either anifrolumab or placebo treatment for 24 weeks. Main inclusion criteria are fulfilment of the ACR/EULAR classification criteria for pSS, disease duration of ≤10 years, and an ESSDAI and/or ESSPRI of ≥5 (at least 50% of patients need to fulfil the ESSDAI ≥5 criterion). The primary outcome measure is Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) response at week 24.


Description:

The aim is to evaluate safety and determine the effects of anifrolumab on essential clinical and biological parameters in patients with primary Sjögren's syndrome (pSS). Although the pathogenesis of pSS has not been fully elucidated, one of the key immune pathways involved is type-I IFN signalling. Since anifrolumab is a fully human, IgG1κ monoclonal antibody to type-I interferon receptor subunit 1, the hypothesis is that inhibition of type-I IFN signalling by anifrolumab may reduce glandular and systemic inflammation and attenuate disease activity in patients with pSS. The study population will consist of patients who fulfil 2016 ACR-EULAR criteria for pSS and have active disease, defined by a EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) score ≥5 and/or an unacceptable patient symptom state (EULAR Sjögren Syndrome Patient Reported Index (ESSPRI) score ≥5. The primary endpoint is the Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) at week 24.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date August 1, 2024
Est. primary completion date May 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Written informed consent 2. Female or male aged =18 years 3. Disease duration (time since diagnosis) =10 years. In case of pediatric-onset pSS a disease duration of =15 years is allowed if there is residual gland function (UWS=0.01 or SWS=0.1 ml/min). 4. Fulfilment of 2016 ACR-EULAR classification criteria for pSS (which includes focus score =1 in salivary gland biopsy and/or anti-SSA/Ro positivity), based on previous diagnostic examinations 5. Presence of anti-SSA antibodies 6. ESSDAI=5 and/or ESSPRI=5. ESSDAI=5 implicates a moderate to high systemic disease activity and ESSPRI=5 implicates that the patient-reported symptom state is unacceptable. At least 50% of patients need to fulfil the ESSDAI=5 criterion. Inclusion of patients with low ESSDAI (<5) should be discontinued when 15 included patients (50%) have a low ESSDAI. 7. Willingness to undergo a repeated parotid gland biopsy at baseline and 24 weeks after start treatment. If a recent parotid gland biopsy (within =1 year before the baseline visit) is available, and enough material of this parotid gland biopsy is available, this biopsy can be used as baseline sample. 8. Use of reliable method of contraception for participants of reproductive potential. 9. Vaccinated against COVID-19 (at least two COVID-19 vaccinations) or previous confirmed COVID-19 infection (from which the patient is recovered) in combination with at least one COVID-19 vaccination or a previous confirmed COVID-19 infection (from which the patients has recovered) in combination with a positive anti-SARS-CoV-2 antibody test. Exclusion Criteria: 1. Presence of any other connective tissue disease 2. Positive pregnancy test (urinary HCG) at screening or breast-feeding 3. History of alcohol or drug abuse 4. History of malignancy or with a current suspicion for cancer, apart from local MALT lymphoma, squamous or basal cell carcinoma of the skin treated with documented success of curative therapy =3 months prior to week 0 or cervical cancer in situ treated with apparent success with curative therapy =1 year prior to week 0. 5. Subjects with evidence (as assessed by the investigator) of active or latent bacterial or viral infections at the time of potential enrollment, including subjects with evidence of HIV which will be tested during screening. 6. History of chronic or recurrent serious infections. (e.g. chronic pyelonephritis, osteomyelitis or bronchiectasis). 7. Subjects with serious bacterial infections within the last 3 months, unless treated and resolved with antibiotics. 8. Opportunistic infection requiring hospitilization or IV antimicrobial treatment within 3 years of randomization 9. Any infection requiring hospitalization or treatment with IV anti-infective medications not completed at least 4 weeks prior to signing the ICF. 10. Subjects with herpes zoster that resolved less than 12 weeks before potential enrollment or any severe case of herpes zoster in a subjects history, including, but not limited to, non-cutaneous herpes (ever), herpes encephalitis (ever), recurrent herpes zoster (defined as 2 episodes within 2 years) or ophthalmic herpes involving the retina (ever). 11. Any clinical cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infection that has not completely resolved within 12 weeks prior to signing the ICF. 12. Any history of severe COVID-19 infection (e.g. requiring hospitalization, ICU care or assisted ventilation) or any prior COVID-19 infection with unresolved sequelae. Any acute COVID-19 infection (lab confirmed or suspected based on clinical symptoms) within the last 3 months prior to screening. 13. Subjects at risk for TB. Specifically excluded from this study will be subjects with a history of active TB; current clinical, radiographic, or laboratory evidence of active TB, which will be tested during screening; history of latent TB, with the exception of latent TB with documented completion of appropriate treatment. 14. Subjects who are positive for hepatitis B surface antigen, which will be tested during screening. 15. Subjects who are positive for hepatitis C antibody if the presence of hepatitis C virus was also shown with polymerase chain reaction or recombinant immunoblot assay, which will be tested during screening. 16. Subjects who have received any live or attenuated vaccines within 8 weeks prior to signing the ICF. 17. Blood transfusion or receipt of blood products within 4 weeks prior to signing the ICF. 18. Underlying cardiac, pulmonary, metabolic, renal, hepatic, gastrointestinal, hematological or neurological conditions, chronic or latent infectious diseases or immune deficiency which places the patient at an unacceptable risk for participation in the study. 19. Preceding treatment with biological DMARDs, including abatacept, anti-TNF or other monoclonal antibodies within 6 months, and rituximab within 12 months from baseline 20. Use of high-dose prednisone, less than 2 weeks before inclusion. Stable low dose (=10 mg) is allowed. 21. Use of hydroxychloroquine, methotrexate, cyclophosphamide, cyclosporine, azathioprine, MMF and leflunomide less than 3 months ago. 22. Use of pilocarpine less than 1 month ago. 23. Lab abnormalities: - Serum creatinine > 2.8 mg/dl (250 µmol/l) - ASAT or ALAT outside 2.5 x upper normal range of the laboratory - Hb < 9 g/dl (5.6 mmol/l) for males and 8.5 g/dl (5.3 mmol/l) for females - Neutrophil granulocytes less than 0.5 x 109/l - Platelet count less than 50 x 109/l 24. Any other laboratory test results that, in the opinion of the investigator, might place a subject at unacceptable risk for participation in the study. 25. A known history of allergy or reaction to any component of the IP formulation or history of anaphylaxis to any human gamma globuline therapy. 26. Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site) 27. Previous enrolment or randomisation in the present study 28. Participation in another clinical study with an investigational drug during the last 6 months, or local investigational product during the last month

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Anifrolumab
Anifrolumab 300 mg will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
Placebo
Placebo will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.

Locations

Country Name City State
Netherlands University Medical Centre Groningen Groningen

Sponsors (2)

Lead Sponsor Collaborator
University Medical Center Groningen AstraZeneca

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) response The CRESS is a recently developed composite endpoint which consists of five clinically relevant items for pSS: a systemic disease activity, patient-reported symptoms, tear gland, salivary gland and serology item. A CRESS responder is someone who reached response on at least three out of five items (Arends et al., https://doi.org/10.1016/S2665-9913(21)00122-3) Week 24
Secondary Safety (adverse events and tolerability) Adverse events and tolerability Weeks 0, 4, 8, 12, 16, 20 and 24
Secondary Total CRESS response The CRESS is a recently developed composite endpoint which consists of five clinically relevant items for pSS: a systemic disease activity, patient-reported symptoms, tear gland, salivary gland and serology item. A CRESS responder is someone who reached response on at least three out of five items (Arends et al., https://doi.org/10.1016/S2665-9913(21)00122-3) Week 12
Secondary ClinESSDAI Change in ClinESSDAI from baseline, scale 0-135. A higher score means a worse outcome. Weeks 0, 8, 12, 20, 24
Secondary ESSPRI Change in ESSPRI from baseline, scale 0-10. A higher score means a worse outcome. Weeks 0, 8, 12, 20, 24
Secondary Schirmer's test Change in Schirmer's test from baseline, scale 0-35 mm. A higher score means a better outcome. Weeks 0, 12, 24
Secondary Ocular Staining Score (OSS) Change in OSS from baseline, scale 0-12. A higher score means a worse outcome Weeks 0, 12, 24.
Secondary Salivary gland ultrasonography (SGUS) Change in total Hocevar score (0-48) from baseline. A higher score means a worse outcome. SGUS: weeks 0, 12, 24
Secondary Rheumatoid factor (RF) Change in RF (IU/ml) from baseline. A higher score means a worse outcome. Weeks 0, 8, 12, 20, 24
Secondary Total IgG Change in IgG (g/L) from baseline. A higher score means a worse outcome. Weeks 0, 8, 12, 20, 24
Secondary Unstimulated whole salivary secretion (UWS) Change in UWS (reported in ml/min) from baseline. A higher score means a better outcome. Weeks 0, 12, 24.
Secondary ESSDAI Change in ESSDAI from baseline, scale 0-123. A higher score means a worse outcome. Weeks 0, 8, 12, 20, 24
Secondary (Clin)ESSDAI minimal clinically important improvement (MCII) (Clin)ESSDAI MCII is defined as a decrease of =3 points Weeks 8, 12, 20, 24
Secondary (Clin)ESSDAI low disease activity (Clin)ESSDAI low disease activity is defined as a score<5 Weeks 8, 12, 20, 24
Secondary Physician GDA (PhGDA) Change in PhGDA from baseline, scale 0-10. A higher score means a worse outcome. Weeks 0, 8, 12, 20, 24
Secondary NRS score oral, ocular and vaginal dryness Change in NRS score from baseline, scale 0-10. A higher score means a worse outcome. Weeks 0, 8, 12, 20, 24
Secondary Patient GDA (PtGDA) Change in PtGDA from baseline, scale 0-10. A higher score means a worse outcome. Weeks 0, 8, 12, 20, 24
Secondary Short Form-36 (SF-36) health survey The SF-36 includes 8 domains, each ranging on a scale from 0-100. A higher score means a better outcome. Weeks 0, 12, 24
Secondary EurQoL 5 dimensions (EQ-5D) measure of health-related quality of life The EQ-5D is reported as index value (0-1). A higher score means a better outcome. Weeks 0, 8, 12, 20, 24
Secondary Multidimensional Fatigue Index (MFI) scale The MFI is reported on a scale of 4-20 for both physical and mental fatigue. A higher score means a worse outcome. Weeks 0, 12, 24
Secondary Female Sexual Function Index (FSFI) in females The FSFI total score has a range of 2-36. A higher score indicates better outcome. Weeks 0, 12, 24
Secondary SGUS OMERACT score The OMERACT score is reported on a scale of 0-3. A higher score means a worse outcome. Weeks 0, 12, 24
Secondary Parotid gland histology: focus score Number of foci / 4 mm2 Week 0, 24
Secondary Parotid gland histology: area of CD45 infiltrate Change in are of CD45 infiltrate at week 24 compared to week 0 Week 0, 24
Secondary Serum levels of anti-SSA/SSB U/ml Weeks 0, 8, 12, 20, 24
Secondary Complement (C3/C4) g/L Weeks 0, 8, 12, 20, 24
Secondary Lymphocyte count 10^9/L Weeks 0, 8, 12, 20, 24
Secondary Presence of cryoglobulinemia Presence of cryoglobulinemia (yes/no) will be analysed at week 0, 12 and 24. Weeks 0, 12, 24
See also
  Status Clinical Trial Phase
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT04968912 - A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS) Phase 2
Completed NCT03203382 - Corneal Nerve Structure in Sjogren's
Completed NCT00809003 - Assessment of Inflammatory and Functional Changes in the Ocular Surface Associated With Dry Eye Disease N/A
Completed NCT00023491 - Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells N/A
Completed NCT05005806 - Fish Oil (Omega 3 ) in Sjogren's Syndrome Phase 2/Phase 3
Enrolling by invitation NCT03436576 - Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye Phase 3
Terminated NCT04143841 - Viveye Ocular Magnetic Neurostimulation System (OMNS) for the Management of Severe Dry Eye Disease N/A
Completed NCT03611283 - Topical Management of Xerostomia With Dry Mouth Products N/A
Recruiting NCT06104124 - A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity Phase 3
Recruiting NCT05115487 - Evaluation of Hand Functions in Newly Diagnosed Primary Sjögren's Syndrome
Recruiting NCT06437652 - An AI Algorithm for Lymphocyte Focus Score of Minor Salivary Gland Biopsy Samples for Diagnosing Sjogren's Syndrome
Not yet recruiting NCT03938207 - Dry Eye Syndrome, Healthy Control, Sjögren's Syndrome and Other Inflammation Disease in Taiwan Biobank
Completed NCT04546542 - Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Recruiting NCT05085431 - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome Early Phase 1
Completed NCT00565526 - Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome
Completed NCT01369589 - An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness Phase 1/Phase 2
Completed NCT00001953 - The Functioning of Immune and Hormonal Systems in Patients With Sjogren's Syndrome and in Healthy Volunteers N/A
Completed NCT00001731 - Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops Phase 2